EUNICE GBENOBA: Open Payments
NPI 1336173327 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$323 in 16 payments from 11 companies in 2025. Trend: 2023 $112 · 2024 $166 · 2025 $323
Food & beverage: $323
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 4 | $63 |
| Corcept Therapeutics | 2 | $44 |
| Novo Nordisk Inc | 2 | $30 |
| CeQur Corporation | 1 | $26 |
| Xeris Pharmaceuticals, Inc. | 1 | $26 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $26 |
| Alvogen Inc | 1 | $25 |
| Blueprint Medicines Corporation | 1 | $21 |
| Madrigal Pharmaceuticals | 1 | $21 |
| Ascensia Diabetes Care Us Inc. | 1 | $20 |
Products named: MOUNJARO, Korlym, Wegovy, CeQur Simplicity, GVOKE HYPOPEN, Kerendia, TERIPARATIDE, AYVAKIT.
Industry payments across TX — which companies pay providers there.
